HOME >> MEDICINE >> NEWS
Molecular imaging may lead to earlier diagnosis of childhood respiratory virus

"Most pathologists look at thick sections of RSV in formaldehyde, but our 3D structures are more fluid and amorphous than the solid structures pathologists have observed," Santangelo said. "The more we know about how RSV really looks, the more we'll understand about its pathogenesis."

RSV is the most important cause of respiratory infection in young children worldwide, infecting virtually every child in the first few years of life. Immunity is feeble and fleeting, and repeated infections are the rule. One in every 100 or 200 infected infants requires hospitalization, usually for bronchiolitis. There is not yet an effective vaccine for RSV, and current anti-viral drugs are in their infancy in terms of efficacy, Santangelo noted.

Ultimately, researchers want to conduct in vivo testing, but must first adapt their molecular beacons technology for that purpose, Santangelo said. "In the nearer term, we hope to use molecular beacons to detect RSV in clinical samples like with those taken with a nasal swab. We might be able to detect RSV in its first day of incubation and make an early diagnosis,'' he added.

The researchers also hope their research will lead to development of a suite of anti-viral drugs for treating RSV and other viruses, including human influenza.


'"/>

Contact: Jane Sanders
jsanders@gatech.edu
404-894-2214
Georgia Institute of Technology Research News
18-Apr-2006


Page: 1 2 3

Related medicine news :

1. Elsevier launches Molecular Oncology
2. Molecular marker may help identify pancreatic cancer, and possibly predict survival time
3. Molecular differences between early and advanced melanomas could provide new drug targets
4. Molecular structure reveals how botulinum toxin attaches to nerve cells
5. Molecular medicine comes to the rescue
6. Molecular switch may turn off immune cells that target HIV
7. The Molecular Profiling Institute, Inc. and IBM advance technology
8. Molecular Profiling Institute secures $7.5 million in Series B funding
9. Molecular studies in cancer of the colon
10. Molecular ballet unravels, links proteins so cell can direct own movement
11. Molecular testing in patients with rare cancer predicts response to Gleevec

Post Your Comments:
(Date:4/26/2015)... New York, New York (PRWEB) April 26, 2015 ... convened on April 21, 2015 in the U.S. ... of federally-filed testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) ... pretrial proceedings. According to court documents, matters addressed ... to seek dismissal of claims involving their products ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 Italian public ... deadly legacy of asbestos cement plants and other asbestos-related ... the new research. Click here to read it ... Italy’s Department of Occupational and Environmental Medicine analyzed more ... and found 32 clusters where the asbestos cancer was ...
(Date:4/26/2015)... 26, 2015 Compare-autoinsurance.org has released a new ... quotes . , The easiest way to find low cost ... access to the best offers online, in a simple and ... providers for information about auto insurance prices. All the details ... page. , It is now possible to compare online ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 Indiana Fiber ... provider announces that Brotherhood Mutual Insurance Company has selected ... Manager of Network Infrastructure at Brotherhood Mutual Insurance Company ... the service reliability Brotherhood Mutual needed. We ... and IFN worked with us to ensure we achieved ...
(Date:4/26/2015)... With the FCPX LUT B&W pack from ... can quickly and easily add desaturated color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 60 black and white CUBE LUT files. ... and white films. With the FCPX LUT B&W Loader ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 4Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
(Date:4/23/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $422.5 million, a 6 percent ... (a 13 percent increase on a constant currency basis).  ... percent compared to the quarter ended March 31, 2014.  ... an increase of 2 percent compared to the quarter ...
(Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4
Cached News: